Publications:96
Alessandro Lagana, PhD
About Me
Alessandro is an Assistant Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai. His main research interests are in the fields of integrative cancer genomics, cancer network biology and precision oncology.
The aim of Alessandro's research is the development and application of computational methods for integrative analysis of multi-omics data to:
- Investigate the role of coding and non-coding alterations on cancer pathogenesis and progression;
- Understand the clinical implications of intra-tumor heterogeneity and of the tumor microenvironment;
- Inform patient risk stratification;
- Develop personalized therapy selection approaches guided by next-generation sequencing technologies.
Alessandro's current research focuses on Multiple Myeloma, a genetically complex and heterogeneous malignancy of bone marrow plasma cells affecting more than 30,000 patients each year in the United States. The causal drivers of Myeloma pathogenesis are still unclear, and treatment is administered empirically on the basis of recurrence risk rather than genetic events.
Alessandro is leading the development of a precision medicine pipeline that has been successfully applied in a clinical trial to guide treatment of relapsed Multiple Myeloma patients. The goal of precision oncology is to devise optimal treatment strategies tailored to the characteristics of the individual patient’s disease. However, the widespread heterogeneity of cancer patients and drug responses pose a significant challenge in the design of effective personalized treatments. Alessandro's research addresses this extremely important challenge and aims to transform the current paradigm of empirical clinical application. The systematic use of integrative genomics, systems biology approaches, big-data analytics and novel sequencing technologies will enable physicians to provide more precise and effective personalized treatment of cancer.
Education
M.Sc. University of Catania, Catania, Italy
Ph.D. University of Catania, Catania, Italy
Language
English
Position
ASSISTANT PROFESSOR | Oncological Sciences, ASSISTANT PROFESSOR | Genetics and Genomic Sciences
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Genetics and Genomic Sciences [GGS]
Publications
Selected Publications
- Degrading NSD2 rewires the myeloma niche. Alessandro Laganà. Blood
- Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies. Lucia Y. Chen, Adolfo Aleman, Marta Larrayoz, Hsiling Chiu, Junfei Zhao, Oliver Van Oekelen, Geoffrey Kelly, Seunghee Kim-Schulz, Alessandro Lagana, Sundar Jagannath, Tracy T. Chow, Teresa Lozano, Juan J. Lasarte, Joseph Hamley, Warren Baker, Benjamin L. Ebert, Udo Oppermann, Michael Amatangelo, Anita K. Gandhi, Patrick R. Hagner, Jose A. Martinez-Climent, Sarah Gooding, Thomas A. Milne, Samir Parekh. Blood
- Retraction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation. Flavia Pichiorri, Dario Palmieri, Luciana De Luca, Jessica Consiglio, Jia You, Alberto Rocci, Tiffany Talabere, Claudia Piovan, Alessandro Lagana, Luciano Cascione, Jingwen Guan, Pierluigi Gasparini, Veronica Balatti, Gerard Nuovo, Vincenzo Coppola, Craig C. Hofmeister, Guido Marcucci, John C. Byrd, Stefano Volinia, Charles L. Shapiro, Michael A. Freitas, Carlo M. Croce. The Journal of experimental medicine
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Lagana did not report having any of the following types of financial relationships with industry and other outside entities during 2025 and/or 2026: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.